

<b>FORM PTO-1449</b>  <b>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b>  (use several sheets if necessary)	<b>SERIAL NO.</b>	<b>CASE NO.</b>
	09/199,860	P-162
	<b>FILING DATE</b> NOVEMBER 25, 1998	<b>GROUP ART UNIT</b> 1614
<b>APPLICANT(S):</b> PAMUKCU ET AL.		

**REFERENCE DESIGNATION****U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	A1	4,950,680	08/21/90	Taylor et al.		

11002 U.S. PTO  
10/07/1639  
02/07/02

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
	A2	WO 95/19978	07/27/95	WO		X

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

Docket Number (Optional) <b>P-162</b>	Application Number <b>09/199,860</b>
Applicant(s) <b>Panukcu et al.</b>	
Filing Date <b>11/25/98</b>	Group Art Unit <b>1614</b>

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

11002 U.S. PRO  
10/07/1639  
02/07/02

**FOREIGN PATENT DOCUMENTS**

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
		WO 00/15222	03/23/00					

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)


EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

SERIAL NO.

09/199.860

CASE NO.

P-162

**LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE STATEMENT**

(use several sheets if necessary)

FILING DATE

NOVEMBER 25, 1998

GROUP ART UNIT

1614

APPLICANT(S): PAMUKCU ET AL.

**REFERENCE DESIGNATION**

## U.S. PATENT DOCUMENTS

[illegible]

**FOREIGN PATENT DOCUMENTS**

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO	

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
	A2	Blaya, C. et al., Effect of the protein kinase inhibitors, 1-(5-isoquinoliny)sulfonyl)-2-methylpiperazine H-7 and N-(2-[methylamino]ethyl)-5-isoquinoline-sulfonamide H-8 on Lewis lung carcinoma tumor progression, European Journal of Pharmacology, 354, pp. 99-104 (1998)
	A3	Chang, W. et al., Sulindac Sulfone Modulates the Expression and Cellular Localization of b-Catenin in Human Colon Carcinoma Cells, Digestive Disease Week, April 1, 1999
	A4	Earnest, D. et al., Piroxicam and Other Cyclooxygenase Inhibitors: Potential for Cancer Chemoprevention, Journal of Cellular Biochemistry, Supplement 161:156-166 (1992)
	A5	Easwaran, V. et al., The Ubiquitin-Proteasome Pathway and Serine Kinase Activity Modulate Adenomatous Polyposis Coli Protein-mediated Regulation of $\beta$ -Catenin-Lymphocyte Enhancer-binding Factor Signaling, The Journal of Biological Chemistry, Vol. 274, No. 23, pp. 16641-16645, June 4, 1999
	A6	Jiang, X. et al., Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells, Proc. Natl. Acad. Sci. USA, Vol. 83, pp. 11236-11241, October 1996
	A7	Korinek, V. et al., Constitutive Transcriptional Activation by a $\beta$ -Catenin-Tcf Complex in APC <sup>-/-</sup> Colon Carcinoma, Science, Vol. 275, pp. 1784-1786, 21 March 1997

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449</b>  <b>LIST OF PATENTS AND PUBLICATIONS FOR</b> <b>APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b> (use several sheets if necessary)	<b>SERIAL NO.</b>	<b>CASE NO.</b>
	09/199,860	P-162
	<b>FILING DATE</b>	<b>GROUP ART UNIT</b>
	NOVEMBER 25, 1998	1614
<b>APPLICANT(S):</b> PAMUKCU ET AL.		

**REFERENCE DESIGNATION U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO

EXAMINER INITIAL	<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)</b>	
	A8	Mahmoud, N. et al., <i>Apc</i> Gene Mutation is Associated with a Dominant-Negative Effect upon Intestinal Cell Migration. <i>Cancer Research</i> 57, pp. 5045-5050, November 15, 1997
	A9	Mahmoud, N. et al., Genotype-Phenotype Correlation in Murine <i>Apc</i> Mutation: Differences in Enterocyte Migration and Response to Sulindac, <i>Cancer Research</i> 59, pp. 353-359, January 15, 1999
	A10	Morin, P. et al., Activation of $\beta$ -Catenin-Tcf Signaling in Colon Cancer by Mutations in $\beta$ -Catenin or APC, <i>Science</i> , Vol. 275, pp. 1787-1789, 21 March 1997
	A11	Peifer, M., $\beta$ -Catenin as Oncogene: The Smoking Gun, <i>Science</i> , Vol. 275, pp. 1752-1753, 21 March 1997
	A12	Rubinfeld, B. et al., Stabilization of $\beta$ -Catenin by Genetic Defects in Melanoma Cell Lines, <i>Science</i> , Vol. 275, pp. 1790-1792, 21 March 1997

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449</b>  <b>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b>  (use several sheets if necessary)	<b>SERIAL NO.</b> 09/199,860	<b>CASE NO.</b> P-162
	<b>FILING DATE</b> 11/25/98	<b>GROUP</b> 1614
	<b>APPLICANT(S):</b> Rifat Pamukcu et al.	

J1002 U.S. PRO  
 10/071639  
 02/07/02

**REFERENCE DESIGNATION U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/SUBCLASS	FILING DATE
	1	3,031,450	4/24/62	Fischer et al.		
	2	3,161,654	12/15/64	Shen		
	3	3,322,755	5/30/67	Roch et al.		
	4	3,517,005	6/23/70	Cronin et al.		
	5	3,594,480	7/20/71	Cronin et al.		
	6	3,647,858	3/7/72	Hinkley et al.		
	7	3,654,349	4/4/72	Shen et al.		
	8	3,780,040	12/18/73	Schnettler et al.		
	9	3,812,127	5/21/74	Cronin et al.		
	10	3,819,631	6/25/74	Broughton et al.		
	11	3,865,840	2/11/75	John Robert Carson		
	12	3,920,636	11/18/75	Takahasi et al.		
	13	4,001,237	1/4/77	Partyka et al.		
	14	4,001,238	1/4/77	Partyka et al.		
	15	4,039,544	8/2/77	Broughton et al.		
	16	4,060,615	11/29/77	Matier et al.		
	17	4,076,711	02/28/78	Ganguly et al.		
	18	4,079,057	3/14/78	Juby et al.		
	19	4,098,788	7/4/78	Crenshaw et al.		
	20	4,101,548	7/18/78	Crenshaw et al.		
	21	4,102,885	7/25/78	Crenshaw et al.		
	22	4,138,561	2/6/79	Crenshaw et al.		
	23	4,146,718	3/27/79	Jenks et al.		
	24	4,161,595	7/17/79	Kaplan et al.		
	25	4,171,363	10/16/79	Crenshaw et al.		
	26	4,208,521	6/17/80	Crenshaw et al.		
	27	4,209,623	6/24/80	Juby		

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	28	4,423,075	12/27/83	Dvornik et al.		
	29	4,457,927	07/03/84	Biere et al.		
	30	4,460,590	7/17/84	Möller		
	31	4,460,591	7/17/84	DeGraw et al.		
	32	4,880,810	11/14/89	Lowe III et al.		
	33	4,885,301	12/5/89	Coates		
	34	4,923,874	5/8/90	McMahon et al.		
	35	4,971,972	11/20/90	Doll et al.		
	36	5,073,559	12/17/91	Coates		
	37	5,091,431	02/25/92	Tulshian et al.		
	38	5,147,875	9/15/92	Coates et al.		
	39	5,175,151	12/29/92	Afonso et al.		
	40	5,223,501	6/29/93	Chakravarty et al.		
	41	5,250,535	10/5/93	Verheyden et al.		
	42	5,254,571	9/25/92	Coates et al.		
	43	5,358,952	10/25/94	Moschel et al.		
	44	5,376,683	12/27/94	Klar et al.		
	45	5,393,755	02/28/95	Neustadt et al.		
	46	5,401,774	3/28/95	Pamukcu et al.		
	47	5,439,895	8/8/95	Lee et al.		
	48	5,488,055	1/30/96	Kumar et al.		
	49	5,614,530	3/25/97	Kumar et al.		
	50	5,614,627	3/25/97	Takase et al.		
	51	5,696,159	12/9/97	Gross et al.		
	52	5,728,563	03/17/98	Tanaka Toshio; Mie;		
	53	5,756,818	05/26/98	Buchmann et al.		
	54	5,874,440	02/23/99	Pamukcu et al.		
	55	5,852,035	12/22/98	Pamukcu et al.		
	56	5,858,694	01/12/99	Piazza et al.		

#### FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLAT YES NO	
	57	DD 274218	12/13/89	Germany			
	58	DE 3038166 (Abstract only)	1981	Germany		X	

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLAT YES NO	
	59	EP 0 330 004 A1	06/02/89	EPO			
	60	EP 0 347,146 A2	12/20/89	EPO			
	61	EP 0 349,239 A2	1/3/90	EPO			
	62	EP 0 351,058	1/17/90	EPO			
	63	EP 0 352,960 A2	1/31/90	EPO			
	64	EP 0 395,328 A2	10/31/90	EPO			
	65	EP 0 428,268 A2	5/22/91	EPO			
	66	EP 0 463,756 A1	1/2/92	EPO			
	67	EP 0 508,586 A1	10/14/92	EPO			
	68	EP 0 526,004 A1	2/3/93	EPO			
	69	EP 0 607,439 A1	7/27/94	EPO			
	70	EP 0 722,937 A1	7/24/96	EPO		X	
	71	EP 0 743,304 A1	10/05/96	EPO			
	72	GB 807,826	1/21/59	England			
	73	GB 2,063,249 A	6/3/81	England			
	74	JP 56-53659 A	5/13/81	Japan		X <sup>1</sup>	
	75	JP 8-311035	11/26/96	JPO		X	
	76	JP 57-167974 A	10/16/82	Japan		X <sup>1</sup>	
	77	WO 92/03419	3/5/92	PCT			
	78	WO 93/07149	4/15/93	PCT			
	79	WO 93/12095	6/24/93	PCT			
	80	WO 94/05661	3/17/94	PCT			
	81	WO 94/19351	09/01/94	PCT			
	82	WO 94/29277	12/22/94	PCT			
	83	WO 95 18969 A	07/13/95	PCT			
	84	WO 95/26743	10/12/95	PCT			
	85	WO 96/32379	10/17/98	PCT			
	86	WO 97/03070	01/03/97	PCT			
	87	WO 97/03985	2/6/97	PCT			
	88	WO 97/24334	07/10/97	PCT		X	
	89	WO 98/08848	5/3/98	PCT		X	
	90	WO 98/14448	04/09/98	PCT		X	
	91	WO 98/15530	04/16/98	PCT		X	
	92	WO 98/16224	04/23/98	PCT			

<sup>1</sup> Abstract Translation.

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLAT YES NO
	93	WO 98/16521	04/23/98	PCT		
	94	WO 98/17668	04/30/98	PCT		
	95	WO 98/23597	06/04/98	PCT		
	96	WO 98/38168	09/03/98	PCT		

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)		
	97	Waddell, W.R. et al., Am. J. Surgery, Vol. 157, pp. 175-79 (1989)
	98	Gonzaga, R.A.F. et al., The Lancet, 3/30/85, p. 751
	99	Waddell, W.R. et al., J. Surg. Oncology, Vol. 24, pp. 83-87 (1983)
	100	Federation Proceedings (1972) of the Federation of American Societies for Experimental Biology abstract Nos. 2044 and 2045
	101	Gilman, S.C. et al., Nonsteroidal Anti-inflammatory Drugs in Cancer Therapy, (circa 1985)
	102	Brogden, R.N. et al., Drugs, Vol. 16, pp. 97-114 (1978)
	103	Hucker, H.B. et al., Drug Metabolism & Disposition, Vol. 1, No. 6, pp. 721-36 (1973)
	104	Shen, T.Y. et al., Chemical and Biological Studies on Indomethacin, Sulindac and Their Analogs, pp. 107-178 (circa 1975)
	105	Duggan, D.E. et al., Clin. Pharm. & Therapeutics, Vol. 21, No. 3, pp. 326-35 (1976)
	106	Duggan, D.E. et al., J. Pharm. & Exper. Therap., Vol. 201, No. 1, pp. 8-13 (1977)
	107	Glavin, G.B. et al., Toxicology and Applied Pharmacology, Vol. 83, pp. 386-89 (1986)
	108	Moorghen, M. et al., Journal of Pathology, Vol. 156, pp. 341-347 (1988)
	109	Moorghen, M. et al., Acta Histochemica, Suppl.-Band XXIX, S. 195-199 (1990)
	110	Bjarnason et al., Gastroenterology, Vol. 94, No. 4, pp. 1070-74 (1988)
	111	Badrieh, Y., et al., Chem. Ber., Vol. 125, pp. 667-674 (1992)
	112	Silvola, J. et al., Effects of nonsteroidal anti-inflammatory drugs on rat gastric mucosal phosphodiesterase activity, Agents and Actions, Vol. 12.4, pp. 516-520 (1982)
	113	Curtis-Prior, P.B. et al., Cyclic Nucleotide Phosphodiesterase Activity of Human Normal and Carcinomatous Lung Tissue, The Lancet, pp. 1225-1225 December 4, 1976
	114	Pepin, P. et al., Effects of Sulindac and Oltipraz on the tumorigenicity of 4-(methylnitrosamino)-1-(3-pyridyl)-1-Butanone in A/J mouse lung, Carcinogenesis, Vol. 13, No. 3, pp. 341-348 (1992)
	115	Nicholson, C.D. et al. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes, Trends Pharmacol. Sci. (TiPS), Vol. 12, pp. 19-27 (1991)
	116	Ahn, H.S. et al., Effects of Selective Inhibitors on Cyclic Nucleotide Phosphodiesterases of Rabbit Aorta, Biochemical Pharmacology, Vol. 38, No. 19, pp. 3331-3339 (1989)
	117	Luginer, C. et al., Selective Inhibition of Cyclic Nucleotide Phosphodiesterases of Human, Bovine and Rat Aorta, Biochem. Pharmacology, Vol. 35, No. 10, pp. 1743-1751 (1986)
	118	Turner, N.C. et al., Relaxation of guinea-pig trachea by cyclic AMP phosphodiesterase inhibitors and their enhancement by sodium nitroprusside, Br. J. Pharmacol. Vol. III, pp. 1047-1052 (1994)



119	Weishaar, R.E. et al., Multiple Molecular Forms of Cyclic Nucleotide Phosphodiesterase in Cardiac and Smooth Muscle and In Platelets, <i>Biochem. Pharmacology</i> , Vol 35, No. 5, pp. 787-800 (1986)
120	Murray, K.J. et al., Potential Use of Selective Phosphodiesterase Inhibitors in the Treatment of Asthma, <i>New Drugs for Asthma Therapy</i> , Birkhauser Verlag Basel, pp. 27-46 (1991)
121	Sacki, T. et al., Isolation of Cyclic Nucleotide Phosphodiesterase Isozymes From Pig Aorta, <i>Biochem. Pharmacology</i> , Vol 46, No. 5, pp. 833-839 (1993)
122	Turner, N.C. et al., Pulmonary effects of type V cyclic GMP specific phosphodiesterase inhibition in anaesthetized guinea-pig. <i>Br. J. Pharmacol.</i> , Vol. 111, 1198-1204 (1994)
123	Ferreira, S.H. et al., The molecular mechanism of action of peripheral morphine analgesia: stimulation of the cGMP system via nitric oxide release, <i>European Journal of Pharmacology</i> , 201 pp. 121-122 (1991)
124	Hidaka, H. et al., Selective Inhibitors of Three Forms of Cyclic Nucleotide Phosphodiesterase -- Basic and Potential Clinical Applications, Vol. 16, <i>Advances in Cyclic Nucleotide and Protein Phosphorylation Research</i> , pp. 245-259 (1984)
125	Tulshian, D. et al., Synthesis and Phosphodiesterase Activity of Carboxylic Acid Mimetics of Cyclic Guanosine 3',5'-Monophosphate, <i>J. Med. Chem.</i> , Vol. 36, 1210-1220 (1993)
126	Yasumoto, T. et al., Properties of Base-Substituted and Carboxyl-Esterified Analogues of Griseolic Acid, a Potent cAMP Phosphodiesterase Inhibitor, <i>Biochemical Pharmacology</i> , Vol. 43, No. 10, pp. 2073,2081 (1992)
127	Broughton, B.J. et al., Antiallergic Activity of 2-Phenyl-8-azapruin-6-ones, <i>Journal of Medicinal Chemistry</i> , Vol 18, No. 11, pp. 1117-1118 (1975)
128	Kodama, K. et al., Effects of a novel, selective and potent phosphodiesterase type V inhibitor, E4021, on myocardial ischemia in guinea pigs, <i>Euro. J. of Pharma.</i> 263, pp. 93-99 (1994)
129	Zacharski, L. R. et al., Effect of Mopidamol on Survival in Carcinoma of the Lung and Colon: Final Report of Veterans Administration Cooperative Study No. 188, <i>J. of the Nat'l. Cancer Inst.</i> , Vol. 80, No. 2, pp. 90-96 (1988)
130	Lichtner, R. B. et al., The Pyrimido-pyrimidine Derivatives RA 233 and RX-RA 85 affect Growth and Cytoskeletal Organization of Rat Mammary Adenocarcinoma Cells, <i>Eur. J. Cancer Clin. Oncol.</i> , Vol. 23, No. 9, pp. 1269-1275 (1987)
131	Janik, P. et al., Inhibition of Growth of Primary and Metastatic Lewis Lung Carcinoma Cells by the Phosphodiesterase Inhibitor Isobutylmethylxanthine, <i>Cancer Res.</i> Vol 40, pp. 1950-1954, (June, 1980)
132	Bergstrand, Hakan et al., Effects of Antiallergic Agents, Compound 48/80, and Some Reference Inhibitors on the Activity of Partially Purified Human Lung Tissue Adenosine Cyclic 3',5'-Monophosphate and Guanosine Cyclic 3',5'-Monophosphate Phosphodiesterases, <i>Molecular Pharmacology</i> , 13, pp. 38-43 (1976)
133	Drees, Markus et al., 3',5'-Cyclic Nucleotide Phosphodiesterase in Tumor Cells as Potential Target for Tumor Growth Inhibition, <i>Cancer Research</i> 53, pp. 3058-3061 (1993)
134	Semmler, J. et al., Xanthine derivatives: comparison between suppression of tumor necrosis factor- $\alpha$ production and inhibition of cAMP phosphodiesterase activity, <i>Immunology</i> 78, pp. 520-525 (1993)
135	Mehta, Rajendra et al., Structure-Activity Relationships of Brassinin in Preventing the Development of Carcinogen-Induced Mammary Lesions in Organ Culture, <i>Anticancer Research</i> 14: 1209-1214 (1994)
136	Makaryan, A.P. et al., Cyclic Nucleotides in Patients with Malignant Neoplasms of the

		Colon. Laboratornoe Delo. Vol. 8, pp. 31-33 (1991)
	137	Carter et al., Chemotherapy of Cancer. 2 <sup>nd</sup> Ed., John Wiley & Sons. NY. NY, 1981, pages 362-365
	138	Biddle, William et al., Antineoplastic Effect of the Pyrimido-Pyrimidine Derivative: RA 233. Pathologie Biologie. Jan., 1984. pp. 9-13
	139	Clarke, W.R. et al., The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance (Abstract Only), Pulm. Pharmacol., 7(2), pp. 81-9, (1994)
	140	Rachburn, David et al., Effects of isoenzyme-selective inhibitors of cyclic nucleotide phosphodiesterase on microvascular leak in guinea pig airways in vivo (Abstract Only), J. Pharmacol. Exp. Ther., 267(3), pp. 1147-51 (1993)
	141	Marcoz, P. et al., Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents (Abstract Only), Mol. Pharmacol. 44(5) pp. 1027-35 (1993)
	142	Barnett, Mary S. et al., Initial biochemical and functional characterization of cyclic nucleotide phosphodiesterase isozymes in canine colonic smooth muscle (Abstract Only), J. Pharmacol. Exp. Ther., 264(2) pp. 801-12 (1993)
	143	Molnar-Kimber, K. et al., Modulation of TNF $\alpha$ and IL-1B from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors (Abstract Only), Agents Actions 39(Spec. Conf. Issue), C77-C79 (1993)
	144	Giorgi, Mauro et al., Characterization of 3':5' cyclic nucleotide phosphodiesterase activities of mouse neuroblastoma N18TG2 cells (Abstract Only), FEBS Lett. 324(1) pp. 76-80 (1993)
	145	Porter, Roderick et al., Preparation of 6-phenyl-3-(5-tetrazolyl)pyridin-2(H)-one derivatives as cyclic AMP-dependent protein kinase agonists (Abstract Only), PCT Int. Appl. WO9206085 A1, (9/26/91)
	146	Molnar-Kimber, K. L. et al., Differential regulation of TNF- $\alpha$ and IL-1B production from endotoxin stimulated human monocytes by phosphodiesterase inhibitors (Abstract Only), Mediators Inflammation 1(6) pp. 411-17 (1992)
	147	Radomski, Marek W. et al., Human Colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability of aggregate platelets (Abstract Only), Cancer Res. 51(22) pp. 6073-8 (1991)
	148	Anderson, Thomas L. G. et al., Interactions between isoprenaline, sodium nitroprusside, and isozyme-selective phosphodiesterase inhibitors on ADP-induced aggregation and cyclic Nucleotide levels in human platelets (Abstract Only), J. Cardiovasc. Pharmacol. 18(2) pp. 237-42 (1991)
	149	Souness, John E. et al., Role of Selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,943, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine (Abstract Only), Br. J. Pharmacol. 98(3) pp. 725-34 (1989)
	150	Lichtner, Rosemarie B., The pyrimidopyrimidine derivatives RA233 and RX-RA85 affect cell cycle distribution of two murine tumor cell lines (Abstract Only), Eur. J. Cancer Clin. Oncol. 25(6), pp. 945-51 (1989)
	151	Mamytbekova, A., et al., Antimetastatic effect of flurbiprofen and other platelet aggregation inhibitors (Abstract Only), Neoplasma 33(4), pp. 417-21 (1986)
	152	Hagiwara, Masatoshi et al., Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic CMP phosphodiesterase, on human platelet aggregation (Abstract Only), J. Pharmacol. Exp. Ther. 229(2) pp. 467-71 (1984)
	153	Ho-Sam Ahn et al., Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic

		Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity; J. Med. Chem. 1997, 40, pp. 2196-2210
	154	J.A. Mitchell et al., Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase; Proc. Natl. Acad. Sci. USA, vol. 90, December 1994, pp 11693-11697
	155	J.D. Gaffin et al.: Increased killing of malignant cells by giving indomethacin with methotrexate, page 30; column 1; XP002084860Chemical Abstract, vol. 106, no. 11, March 16, 1987, abstract no. 78377, J.D.
	156	Tsou, K-C. et al. 5'-Nucleotide Phosphodiesterase Isozyme-V as a Marker for Liver Metastases in Breast Cancer Patients. Cancer 54:1788-1793, 1984
	157	Epstein P M et al.; Dep. Pharmacol., Univ. Tex. Med. Sch., M.D. Anderson Hosp., Houston, Tex. 88030, USA BIOSIS 78:140912, "Increased Cyclic Nucleotide Phospho Di Esterase Activity Associated With Proliferation and Cancer in Human and Murine Lymphoid Cells.
	158	Christian Schudt et al., "Phosphodiesterase Inhibitors" The Handbook of Immunopharmacology, Academic Press, 1996, pp. 65-134

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.